News | February 24, 2022
Cadila Healthcare is now Zydus Lifesciences
Zydus unveils its ‘innovation and care’ centric corporate brand identity
Zydus unveils its ‘innovation and care’ centric corporate brand identity
The company has reported total income of Rs. 3715.8 crores during the quarter ended December 31, 2021
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The company had announced the expected date of completion of sale and disposal of the said undertaking is 90 days from the date of signing the Definitive Agreements.
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Subscribe To Our Newsletter & Stay Updated
